Director/PDMR Shareholding

GSK PLC

11 February 2026

 

GSK plc (the 'Company')

Vesting of Deferred Annual Bonus Plan Deferred Bonus Awards and Sale of Ordinary Shares and American Depositary Shares

This notification sets out the vesting details for Persons Discharging Managerial Responsibilities ('PDMRs') of Deferred Bonus Awards over Ordinary Shares and American Depositary Shares ('ADS') made in 2023 under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') and subsequent sale of Ordinary Shares and ADS to meet tax liabilities. In accordance with the shareholder approved 2022 Remuneration Policy and the DABP rules, the awards comprised a mandatory bonus deferral only. The three-year restricted period for the awards commenced on 9 February 2023 and ended on 8 February 2026. The awards vested on 9 February 2026. Dividends accrued on the awards during the restricted period.

The awards were granted in 2023 as restricted awards over ADS for US participants and as nil-cost options over Ordinary Shares for all other participants.

The closing prices of Ordinary Shares and of ADS of GSK plc on 9 February 2026 were £21.59 and $59.01.

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Luke Miels
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	60,334
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Luke Miels
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£22.1140	4,549
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	25,742
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£22.0162	13,801
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	25,045
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£22.0057	11,789
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Shobie Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	The vesting of an award granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$0.00	12,522
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Shobie Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	The sale of ADS to meet tax liabilities on the vesting of an award granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$59.0729	6,497
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	34,873
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£22.0998	16,415
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	28,010
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£22.0451	13,185
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Phil Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	18,321
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Phil Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£22.0117	8,633
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	44,631
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£22.0267	21,009
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	21,176
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£22.1186	9,978
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

END